A Phase 1, Double-blind, Randomized Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Dose and Multiple Doses of CG-0416 in Healthy Participants.

NCT07724431 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight and Obesity

Interventions

DRUG: CG-0416

Sponsor

HongKong Curegene Innovation Co., Limited